ReviewFrontiers in medicine2021
The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Relationship of Vitamin D, Spondyloarthritis Activity and Left Ventricular Systolic and Diastolic Function.Journal of clinical medicine · 2026Article
- Serum ICAM-1 and VCAM-1 as markers of endothelial activation in ankylosing spondylitis and psoriatic arthritis: a cross-sectional study.BMC rheumatology · 2026Article
- [Consensus statement of the Austrian Society for Rheumatology and Rehabilitation on the management of increased cardiovascular risk in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis].Wiener klinische Wochenschrift · 2026Article
- Physical Activity for Human and Planetary Health: Incorporating Green Exercise in the Management of Rheumatic Disease.Rheumatic diseases clinics of North America · 2026Review
- The management of spondyloarthritis in sub-Saharan Africa: a real-world cohort from Kinshasa, Democratic Republic of the Congo.Rheumatology advances in practice · 2026Article
- Inflammatory biomarkers in axial spondyloarthritis and the effect of moderate and high-intensity interval training - a narrative review.Molecular biology reports · 2025Review
- Effects on Serum Protein Levels From One Bout of High Intensity Interval Training in Individuals With Axial Spondyloarthritis and Controls.Immunity, inflammation and disease · 2025Article
- Association between grip and core muscle strength in people with axial spondyloarthritis and healthy controls.BMC rheumatology · 2025Article
- Molecular insights into the relationship between sustained CRP elevation and endothelial dysfunction in axial spondyloarthritis.RMD open · 2025Article
- Physical activity in relation to health status, quality of life and compliance with World Health Organization recommendations in patients with axial spondyloarthritis.Arthritis research & therapy · 2025Article
- Review
- The comparative prevalence of comorbidities across rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis.Rheumatology advances in practice · 2025Article
- Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events.Dermatology and therapy · 2025Article
- The Effects of Disease-Modifying Antirheumatic Drugs on Cardiovascular Risk in Inflammatory Joint Diseases: Current Evidence and Uncertainties.Vascular health and risk management · 2025Review
- Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis.Advances in rheumatology (London, England) · 2024Article
- Increased PCSK9 associated with cIMT in AS: A useful marker for subclinical atherosclerosis in patients with ankylosing spondylitis.Archives of rheumatology · 2024Article
- Increased Risk for Pulmonary Embolism among Patients with Ankylosing Spondylitis-Results from a Large Database Analysis.Journal of clinical medicine · 2024Article
- Cross-sectional analysis of cardiovascular disease and risk factors in patients with spondyloarthritis: a real-life evidence from biostar nationwide registry.Rheumatology international · 2024Article
- Time Trend Analysis of Comorbidities in Ankylosing Spondylitis: A Population-Based Study from 53,142 Hospitalizations in Poland.Journal of clinical medicine · 2024Article
- Association of ankylosing spondylitis with cardiovascular disease: a bidirectional two-sample mendelian randomization study.Frontiers in genetics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is an increased cardiovascular (CV) risk in axial spondyloarthritis (axSpA), leading to increased CV mortality and morbidity in these patients. The factors that may explain this enhanced CV risk in axSpA are multiple, including traditional CV risk factors such as smoking, but also the inflammatory process and probably the use of non-steroidal anti-inflammatory drugs (NSAIDs). The CV involvement of axSpA may be detected at an early and pre-clinical stage, using non-invasive techniques. While NSAIDs play a deleterious role in the CV risk of axSpA, TNF inhibitors seem to have a beneficial impact, but this remains to be demonstrated in specific clinical studies. More data are needed to determine the potential effects of IL-17 inhibitors on the CV risk of axSpA. CV comorbidity has been mainly assessed in the radiographic form of axSpA, while limited data are available in patients with the non-radiographic form. The current management of axSpA must consider this CV comorbidity according to the EULAR recommendations. Rheumatologists play a determinant role in the detection of CV risk and current management of these patients is focused on the control of disease activity, suppression of inflammation, screening for and management of traditional CV risk factors, as well as the restriction of NSAID use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.